Site-specific gene therapy for cardiovascular disease

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 2, 2010, Pages 203-213

  Fishbein, Ilia ^a   Chorny, Michael ^a   Levy, Robert J ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Angioplasty; Local delivery; Nanoparticle; Stent; Transgene; Vector

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; ARGININE; BETA GALACTOSIDASE; COLLAGEN; COMPLEMENTARY RNA; FIBRIN GLUE; GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; LENTIVIRUS VECTOR; LIPOSOME; MAGNETIC NANOPARTICLE; MYC PROTEIN; NANOPARTICLE; NITRIC OXIDE; PARVOVIRUS VECTOR; PHOSPHORYLCHOLINE; PLASMID DNA; POLOXAMER; POLYETHYLENEIMINE DERIVATIVE; POLYMER; RECOMBINANT DNA; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TETRAHYDROBIOPTERIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN;

BALLOON CATHETER; CARDIOVASCULAR DISEASE; DRUG ELUTING STENT; ELUTION; GENE THERAPY; HEART INFARCTION; HUMAN; HUMAN GENOME; IN-STENT RESTENOSIS; MATERIAL COATING; NEEDLE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROMOTER REGION; RESTENOSIS; REVIEW; RNA INTERFERENCE; STENT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CARDIOVASCULAR DISEASES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS;

EID: 77749270547     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Gene Therapy Clinical Trials Worldwide. John Wiley & Sons Inc, Hoboken, NJ, USA (2009). www.wiley.co.uk/genmed/clinical/
2. Sanz-González SM, Barquín L, García-Cao I, Roque M, González JM, Fuster JJ, Castells MT, Flores JM, Serrano M, Andrés V: Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. Cardiovasc Res (2007) 75(4):803-812.
3. Johnson TW, Wu YX, Herdeg C, Baumbach A, Newby AC, Karsch KR, Oberhoff M: Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler Thromb Vasc Biol (2005) 25(4):754-759.
4. Miyagawa S, Sawa Y, Taketani S, Kawaguchi N, Nakamura T, Matsuura N, Matsuda H: Myocardial regeneration therapy for heart failure: Hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation (2002) 105(21):2556-2561.
5. Laukkanen MO, Kivelä A, Rissanen T, Rutanen J, Karkkainen MK, Leppanen O, Bräsen JH, Yla-Herttuala S: Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation (2002) 106(15):1999-2003.
6. Zoldhelyi P, McNatt J, Shelat HS, Yamamoto Y, Chen ZQ, Willerson JT: Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation (2000) 101(3):289-295.
7. Egashira K, Nakano K, Ohtani K, Funakoshi K, Zhao G, Ihara Y, Koga J, Kimura S, Tominaga R, Sunagawa K: Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler Thromb Vasc Biol (2007) 27(12):2563-2568.
8. Patel VI, Daniel S, Longo CR, Shrikhande GV, Scali ST, Czismadia E, Groft CM, Shukri T, Motley-Dore C, Ramsey HE, Fisher MD, et al: A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia. FASEB J (2006) 20(9):1418-1430.
9. Burton DY, Song C, Fishbein I, Hazelwood S, Li Q, DeFelice S, Connolly JM, Perlstein I, Coulter DA, Levy RJ: The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specifc arrhythmia gene therapy: In vitro and in vivo feasibility studies. Hum Gene Ther (2003) 14(9):907-922.
10. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM: Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther (2008) 15(23):1550-1557.
11. Walter DH, Cejna M, Diaz-Sandoval L, Willis S, Kirkwood L, Stratford PW, Tietz AB, Kirchmair R, Silver M, Curry C, Wecker A, et al: Local gene transfer of phVEGF-2 plasmid by gene-eluting stents. An alternative strategy for inhibition of restenosis. Circulation (2004) 110(1):36-45.
12. Fishbein I, Alferiev I, Bakay M, Stachelek SJ, Sobolewski P, Lai M, Choi H, Chen IW, Levy RJ: Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation (2008) 117(16):2096-2103.
13. Papadakis ED, Nicklin SA, Baker AH, White SJ: Promoters and control elements: Designing expression cassettes for gene therapy. Curr Gene Ther (2004) 4(1):89-113.
14. Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, Nunez-Alonso G, Green AM, Bazzani RP, Sumner-Jones SG, Chan M, et al: CpG-free plasmids confer reduced infammation and sustained pulmonary gene expression. Nat Biotechnol (2008) 26(5):549-551.
15. Kupatt C, Wichels R, Deiss M, Molnar A, Lebherz C, Raake P, von Degenfeld G, Hahnel D, Boekstegers P: Retroinfusion of NFκB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigs. Gene Ther (2002) 9(8):518-526.
16. Li Y, Fukuda N, Kunimoto S, Yokoyama S, Hagikura K, Kawano T, Takayama T, Honye J, Kobayashi N, Mugishima H, Saito S, et al: Stent-based delivery of antisense oligodeoxynucleotides targeted to the PDGF A-chain decreases in-stent restenosis of the coronary artery. J Cardiovasc Pharmacol (2006) 48(4):184-190.
17. Kutryk MJ, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, deFeyter PJ, Bruining N, Sabate M, Serruys PW: Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: Results of the randomized Investigation by the Thoraxcenter of Antisense DNA using Local delivery and IVUS after Coronary Stenting (ITALICS) trial. J Am Coll Cardiol (2002) 39(2):281-287.
18. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J: Interfering with disease: A progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6(6):443-453.
19. Karshovska E, Zernecke A, Sevilmis G, Millet A, Hristov M, Cohen CD, Schmid H, Krotz F, Sohn HY, Klauss V, Weber C, et al: Expression of HIF-1α in injured arteries controls SDF-1α mediated neointima formation in apolipoprotein E defcient mice. Arterioscler Thromb Vasc Biol (2007) 27(12):2540-2547.
20. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, Asnaf V, et al: Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 118(9):3132-3142.
21. Gordon EM, Zhu NL, Forney Prescott M, Chen ZH, Anderson WF, Hall FL: Lesion-targeted injectable vectors for vascular restenosis. Hum Gene Ther (2001) 12(10):1277-1287.
22. Inesi G, Lewis D, Sumbilla C, Nandi A, Strock C, Huff KW, Rogers TB, Johns DC, Kessler PD, Ordahl CP: Cell-specifc promoter in adenovirus vector for transgenic expression of SERCA1 ATPase in cardiac myocytes. Am J Physiol (1998) 274(3 Pt 1):C645-C653.
23. Akyurek LM, Yang ZY, Aoki K, San H, Nabel GJ, Parmacek MS, Nabel EG: SM22α promoter targets gene expression to vascular smooth muscle cells in vitro and in vivo. Mol Med (2000) 6(11):983-991.
24. Gory S, Vernet M, Laurent M, Dejana E, Dalmon J, Huber P: The vascular endothelial-cadherin promoter directs endothelial-specifc expression in transgenic mice. Blood (1999) 93(1):184-192.
25. Horvai A, Palinski W, Wu H, Moulton KS, Kalla K, Glass CK: Scavenger receptor A gene regulatory elements target gene expression to macrophages and to foam cells of atherosclerotic lesions. Proc Natl Acad Sci USA (1995) 92(12):5391-5395.
26. Appleby CE, Kingston PA, David A, Gerdes CA, Umana P, Castro MG, Lowenstein PR, Heagerty AM: A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transfer. Gene Ther (2003) 10(18):1616-1622.
27. Sarkar N, Blomberg P, Wardell E, Eskandarpour M, Sylven C, Drvota V, Islam KB: Nonsurgical direct delivery of plasmid DNA into rat heart: Time course, dose response, and the infuence of different promoters on gene expression. J Cardiovasc Pharmacol (2002) 39(2):215-224.
28. Argyros O, Wong SP, Niceta M, Waddington SN, Howe SJ, Coutelle C, Miller AD, Harbottle RP: Persistent episomal transgene expression in liver following delivery of a scaffold/ matrix attachment region containing non-viral vector. Gene Ther (2008) 15(24):1593-1605.
29. Zhao J, Pettigrew GJ, Thomas J, Vandenberg JI, Delriviere L, Bolton EM, Carmichael A, Martin JL, Marber MS, Lever AM: Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo. Basic Res Cardiol (2002) 97(5):348-358.
30. Wright MJ, Wightman LM, Latchman DS, Marber MS: In vivo myocardial gene transfer: Optimization and evaluation of intracoronary gene delivery in vivo. Gene Ther (2001) 8(24): 1833-1839.
31. Shears LL 2nd, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I, Watkins SC, Tzeng E: Effcient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg (1998) 187(3):295-306.
32. Bangari DS, Mittal SK: Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther (2006) 6(2):215-226.
33. Palmer DJ, Ng P: Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther (2005) 16(1):1-16.
34. Wen S, Graf S, Massey PG, Dichek DA: Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation (2004) 110(11):1484-1491.
35. Fleury S, Driscoll R, Simeoni E, Dudler J, von Segesser LK, Kappenberger L, Vassalli G: Helper-dependent adenovirus vectors devoid of all viral genes cause less myocardial infammation compared with frst-generation adenovirus vectors. Basic Res Cardiol (2004) 99(4):247-256.
36. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH Jr, Weigel-Van Aken KA, Hobbs JA, et al: Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-effciency transduction at lower doses. Proc Natl Acad Sci USA (2008) 105(22):7827-7832.
37. Bish LT, Sleeper MM, Brainard B, Cole S, Russell N, Withnall E, Arndt J, Reynolds C, Davison E, Sanmiguel J, Wu D et al: Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines. Mol Ther (2008) 16(12):1953-1959.
38. Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, Wilson JM, Sweeney L: Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther (2008) 19(12):1359-1368.
39. Dandapat A, Hu CP, Li D, Liu Y, Chen H, Hermonat PL, Mehta JL: Overexpression of TGFβ1 by adeno-associated virus type-2 vector protects myocardium from ischemia-reperfusion injury. Gene Ther (2008) 15(6):415-423.
40. Fishbein I, Alferiev IS, Lai M, Levy RJ: AAV2.9 vectors attain robust and sustained gene expression in two models of vascular gene transfer. Circulation (2007) 116:II-64.
41. Noureddini SC, Curiel DT: Genetic targeting strategies for adenovirus. Mol Pharm (2005) 2(5):341-347.
42. Kreppel F, Kochanek S: Modifcation of adenovirus gene transfer vectors with synthetic polymers: A scientifc review and technical guide. Mol Ther (2008) 16(1):16-29.
43. Perlstein I, Connolly JM, Cui X, Song C, Li Q, Jones PL, Lu Z, DeFelice S, Klugherz B, Wilensky R, Levy RJ: DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: Mechanisms of enhanced transfection. Gene Ther (2003) 10(17):1420-1428.
44. Chorny M, Fishbein I, Alferiev IS, Nyanguile O, Gaster R, Levy RJ: Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression. Mol Ther (2006) 14(3):382-391.
45. French BA, Mazur W, Geske RS, Bolli R: Direct in vivo gene transfer into porcine myocardium using replication-defcient adenoviral vectors. Circulation (1994) 90(5):2414-2424.
46. Li JJ, Ueno H, Pan Y, Tomita H, Yamamoto H, Kanegae Y, Saito I, Takeshita A: Percutaneous transluminal gene transfer into canine myocardium in vivo by replication-defective adenovirus. Cardiovasc Res (1995) 30(1):97-105.
47. Fromes Y, Salmon A, Wang X, Collin H, Rouche A, Hagege A, Schwartz K, Fiszman MY: Gene delivery to the myocardium by intrapericardial injection. Gene Ther (1999) 6(4):683-688.
48. Logeart D, Hatem SN, Heimburger M, Le Roux A, Michel JB, Mercadier JJ: How to optimize in vivo gene transfer to cardiac myocytes: Mechanical or pharmacological procedures? Hum Gene Ther (2001) 12(13):1601-1610.
49. Donahue JK, Kikkawa K, Thomas AD, Marban E, Lawrence JH: Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Ther (1998) 5(5):630-634.
50. Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK, Dec GW, Semigran MJ, Rosenzweig A: Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA (1998) 95(9):5251-5256.
51. Boekstegers P, von Degenfeld G, Giehrl W, Heinrich D, Hullin R, Kupatt C, Steinbeck G, Baretton G, Middeler G, Katus H, Franz WM: Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther (2000) 7(3):232-240.
52. Sasano T, Kikuchi K, McDonald AD, Lai S, Donahue JK: Targeted high-effciency, homogeneous myocardial gene transfer. J Mol Cell Cardiol (2007) 42(5):954-961.
53. Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ: Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv (2002) 55(3):392-397.
54. Vale PR, Losordo DW, Milliken CE, McDonald MC, Gravelin LM, Curry CM, Esakof DD, Maysky M, Symes JF, Isner JM: Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation (2001) 103(17):2138-2143.
55. Carpi F, Pappone C: Stereotaxis Niobe magnetic navigation system for endocardial catheter ablation and gastrointestinal capsule endoscopy. Expert Rev Med Devices (2009) 6(5):487-498.
56. Thompson MM, Budd JS, Eady SL, James RF, Bell PR, Steg PG, Feldman LJ, Scoazec JY, Tahlil O, Barry JJ, Boulechfar S, et al: A method to transluminally seed angioplasty sites with endothelial cells using a double balloon catheter. Eur J Vasc Surg (1993) 7(2):113-121.
57. Tahlil O, Brami M, Feldman LJ, Branellec D, Steg PG: The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res (1997) 33(1):181-187.
58. Plante S, Dupuis G, Mongeau CJ, Durand P: Porous balloon catheters for local delivery: Assessment of vascular damage in a rabbit iliac angioplasty model. J Am Coll Cardiol (1994) 24(3):820-824.
59. Riessen R, Rahimizadeh H, Blessing E, Takeshita S, Barry JJ, Isner JM: Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum Gene Ther (1993) 4(6):749-758.
60. Barath P, Popov A, Dillehay GL, Matos G, McKiernan T: Infltrator angioplasty balloon catheter: A device for combined angioplasty and intramural site-specifc treatment. Cathet Cardiovasc Diagn (1997) 41(3):333-341.
61. Morishige K, Shimokawa H, Yamawaki T, Miyata K, Eto Y, Kandabashi T, Yogo K, Higo T, Egashira K, Ueno H, Takeshita A: Local adenovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo. J Am Coll Cardiol (2000) 35(4):1040-1047.
62. Maiellaro K, Taylor WR: The role of the adventitia in vascular infammation. Cardiovasc Res (2007) 75(4):640-648.
63. Villa AE, Guzman LA, Poptic EJ, Labhasetwar V, D'Souza S, Farrell CL, Plow EF, Levy RJ, DiCorleto PE, Topol EJ: Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res (1995) 76(4):505-513.
64. Desai SD, Blanchard J: Evaluation of Pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model. J Pharm Sci (1998) 87(10):1190-1195. (Pubitemid 28455607)
65. Van Belle E, Maillard L, Rivard A, Fabre JE, Couffnhal T, Kearney M, Branellec D, Feldman LJ, Walsh K, Isner JM: Effects of poloxamer 407 on transfection time and percutaneous adenovirus-mediated gene transfer in native and stented vessels. Hum Gene Ther (1998) 9(7):1013-1024.
66. Khurana VG, Weiler DA, Witt TA, Smith LA, Kleppe LS, Parisi JE, Simari RD, O'Brien T, Russell SJ, Katusic ZS: A direct mechanical method for accurate and effcient adenoviral vector delivery to tissues. Gene Ther (2003) 10(5):443-452.
67. Wan L, Li D, Wu Q: Perivenous application of fbrin glue as external support enhanced adventitial adenovirus transfection in rabbit model. J Surg Res (2006) 135(2):312-316.
68. Lei P, Padmashali RM, Andreadis ST: Cell-controlled and spatially arrayed gene delivery from fbrin hydrogels. Biomaterials (2009) 30(22):3790-3799.
69. Pakkanen TM, Laitinen M, Hippelainen M, Hiltunen MO, Alhava E, Yla-Herttuala S: Periadventitial lacZ gene transfer to pig carotid arteries using a biodegradable collagen collar or a wrap of collagen sheet with adenoviruses and plasmid-liposome complexes. J Gene Med (2000) 2(1):52-60.
70. Serruys PW, Kutryk MJ, Ong AT: Coronary-artery stents. N Engl J Med (2006) 354(5):483-495.
71. Butt M, Connolly D, Lip GY: Drug-eluting stents: A comprehensive appraisal. Future Cardiol (2009) 5(2):141-157.
72. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R: Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation (2007) 115(8):1051-1058.
73. Yutani C, Ishibashi-Ueda H, Suzuki T, Kojima A: Histologic evidence of foreign body granulation tissue and de novo lesions in patients with coronary stent restenosis. Cardiology (1999) 92(3):171-177.
74. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ: Marked infammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 94(7):1690-1697.
75. Fishbein I, Alferiev IS, Nyanguile O, Gaster R, Vohs JM, Wong GS, Felderman H, Chen IW, Choi H, Wilensky RL, Levy RJ: Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proc Natl Acad Sci USA (2006) 103(1):159-164.
76. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J: Magnetic nanoparticles for drug delivery. Nano Today (2007) 2(3):22-32.
77. McBain SC, Yiu HH, Dobson J: Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine (2008) 3(2):169-180.
78. Chorny M, Fishbein I, Levy RJ: Effcient magnetically driven gene delivery in cultured vascular cells and in the rat carotid stenting model using adenovirus-impregnated nanoparticles. Mol Ther (2008) 16(1S):Abs 325.
79. Chorny M, Fishbein I, Alferiev I, Levy RJ: Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells. Mol Pharm (2009) 6(5):1380-1387.
80. Chorny M, Fishbein I, Levy RJ: Endothelial cells transduced with magnetically responsive nanoparticles formulated with iNOS encoding adenovirus inhibit proliferation of aortic smooth muscle cells in a direct co-culture model. Mol Ther (2009) 17(1S):Abs 1035.
81. Yellen BB, Forbes ZG, Halverson DS, Fridman G, Barbee KA, Chorny M, Levy R, Friedman G: Targeted drug delivery to magnetic implants for therapeutic applications. J Magn Magn Mater (2005) 293(1):647-654.
82. Polyak B, Fishbein I, Chorny M, Alferiev I, Williams D, Yellen B, Friedman G, Levy RJ: High feld magnetic gradients can target magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci USA (2008) 105(2): 698-703.
83. O'Connor DM, O'Brien T: Nitric oxide synthase gene therapy: Progress and prospects. Expert Opin Biol Ther (2009) 9(7): 867-878.
84. Naseem KM: The role of nitric oxide in cardiovascular diseases. Mol Aspects Med (2005) 26(1-2):33-65.
85. Li W, Ma N, Ong LL, Nesselmann C, Klopsch C, Ladilov Y, Furlani D, Piechaczek C, Moebius JM, Lützow K, Lendlein A, et al: Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells (2007) 25(8):2118-2127.
86. Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN, Hay JG: Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther (2007) 15(11):1982-1990.
87. Roncalli J, Tongers J, Renault MA, Losordo DW: Biological approaches to ischemic tissue repair: Gene-and cell-based strategies. Expert Rev Cardiovasc Ther (2008) 6(5):653-668.
88. Penn MS, Mangi AA: Genetic enhancement of stem cell engraftment, survival, and effcacy. Circ Res (2008) 102(12): 1471-1482.
89. Kong D, Melo LG, Mangi AA, Zhang L, Lopez-Ilasaca M, Perrella MA, Liew CC, Pratt RE, Dzau VJ: Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation (2004) 109(14):1769-1775.
90. Spadaccio C, Chello M, Trombetta M, Rainer A, Toyoda Y, Genovese JA: Drug releasing systems in cardiovascular tissue engineering. J Cell Mol Med (2009) 13(3):422-439.
91. Channon KM, Qian H, George SE: Nitric oxide synthase in atherosclerosis and vascular injury: Insights from experimental gene therapy. Arterioscler Thromb Vasc Biol (2000) 20(8): 1873-1881.
92. Staudacher DL, Flugelman MY: Cell and gene therapies in cardiovascular disease with special focus on the no option patient. Curr Gene Ther (2006) 6(6):609-623.